摘要
目的探讨切除修复交叉互补基因1(ERCC1)第118位密码子(C118T)和着色性干皮病基因D(XPD)第751位密码子(Lys751Gln)的单核苷酸多态性(SNPs)与晚期非小细胞肺癌(NSCLC)患者含铂类药物化疗疗效的关系。方法用PCR-限制性片段长度多态性(PCR-RFLP)技术检测78例NSCLC患者的ERCC1(C118T)和XPD(Lys751Gln)基因型。结果 ERCC1(C118T)、XPD(Lys751Gln)SNPs不受年龄、性别、吸烟史、临床分期、体力状况评分(ECOG)和病理类型影响;ERCC1(C118T)中不同的年龄、性别、吸烟史和ECOG评分之间化疗疗效差异无统计学意义。ERCC1(C118T)SNPs与含铂类药物化疗疗效有关。结论含有T等位基因可作为预测晚期NSCLC患者铂类药物化疗敏感性的预测指标。
Objective To investigate whether SNPs of ERCC1（C118T） and XPD（Lys751Gln） were associated with the sensitivity of non-small-cell lung cancer（NSCLC） to platinum-based chemotherapy in the patients with advanced NSCLC.Methods Polymorphisms of ERCC1 and XPD were detected by PCR-restrictive fragment length polymorphism（PCR-RFLP） method in 78 cases.Results No association was detected between polymorphisms of ERCC1 and XPD and age,sex,histologic type,ECOG performance status,smoking history and clinical stage of tumor.The difference of clinical response was not found among age,sex,ECOG performance status and smoking history（P0.05）.The polymorphic genotypes of ERCC1（C118T） were related to the sensitivity to platinum-based chemotherapy.Conclusion The patients carrying at least 1 T allele（T/T＋C/T） may be taken as a marker to predict the sensitivity of NSCLC to platinum-based chemotherapy.
出处
《江苏医药》
CAS
北大核心
2013年第3期303-305,共3页
Jiangsu Medical Journal
基金
苏州市社会发展指导计划(SZD0877)
关键词
切除修复交叉互补基因1
着色性干皮病基因D
顺铂
基因多态性
非小细胞肺癌
Excision repair cross-complementing complementation group 1
Xeroderma pigmentosum group D
Cisplatin
Genes polymorphism
Non-small cell lung cancer
